Evidence of Placental Villous Inflammation and Apoptosis in Third-Trimester Symptomatic SARS-CoV-2 Maternal Infection

다국어 초록 (Multilingual Abstract)

Purpose: In view of conflicting reports on the ability of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) to infect placental tissue, this study aimed to further evaluate the impact of inflammation and placental damage from symptomatic third trimester maternal COVID-19 infection.
Materials and Methods: This case-control study included 32 placenta samples each from symptomatic COVID-19 pregnancy and normal non-COVID-19 pregnancy. The villous placental area’s inflammatory expression [angiotensin converting enzyme-2 (ACE-2), transmembrane protease serine-2 (TMPRSS2), interferon-γ (IFN-γ), interleukin-6 (IL-6), and SARS-CoV-2 spike protein] and apoptotic rate were examined using immunohistochemistry and Terminal deoxynucleotidyl transferase dUTP Nick- End La beling (TUNEL) assay. Comparison and correlation analysis were used based on COVID-19 infection, placental SARS-CoV-2 spike protein evidence, and maternal severity status.
Results: Higher expressions of TMPRSS2, IFN-γ, and trophoblast apoptotic rate were observed in the COVID-19 group (p<0.001), whereas ACE-2 and IL-6 expressions were not significantly different from the control group (p>0.05). Additionally, SARS-CoV-2 spike protein was detected in 8 (25%) placental samples of COVID-19 pregnancy. COVID-19 subgroup analysis revealed in creased IFN-γ, trophoblast, and stromal apoptosis (p<0.01). Moreover, the results of the current study revealed no correlation be tween maternal COVID-19 severity and placental inflammation as well as the apoptotic process.
Conclusion: The presence of SARS-CoV-2 spike protein as well as altered inflammatory and apoptotic processes may indicate the presence of placental disturbance in third-trimester maternal COVID-19 infection. The lack of correlation between placental dis ruption and maternal severity status suggests the need for more research to understand the infection process and any potential long-term impacts on all offsprings born to COVID-19-infected pregnant women.

참고문헌 (Reference)

• 1 Algarroba GN, "Visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy" 223 : 275-278, 2020
• 2 Patanè L, "Vertical transmission of coronavirus disease 2019 : severe acute respiratory syndrome coronavirus 2 RNA on the fetal side of the placenta in pregnancies with coronavirus disease 2019-positive mothers and neonates at birth" 2 : 100145-, 2020
• 3 Kotlyar AM, "Vertical transmission of coronavirus disease 2019 : a systematic review and meta-analysis" 224 : 35-53, 2021
• 4 Vivanti AJ, "Transplacental transmission of SARS-CoV-2 infection" 11 : 3572-, 2020
• 5 Joshi B, "The placental pathology in coronavirus disease 2019 infected mothers and its impact on pregnancy outcome" 127 : 1-7, 2022
• 6 Robert-Gangneux F, "The placenta : a main role in congenital toxoplasmosis?" 27 : 530-536, 2011
• 7 Ioannidis JPA, "The end of the COVID-19 pandemic" 52 : e13782-, 2022
• 8 Ouyang Y, "Term human placental trophoblasts express SARS-CoV-2 entry factors ACE2, TMPRSS2, and furin" 6 : e00250-21-, 2021
• 9 Agostinis C, "SARS-CoV-2 modulates virus receptor expression in placenta and can induce trophoblast fusion, inflammation and endothelial permeability" 13 : 957224-, 2022
• 10 Hosier H, "SARS-CoV-2 infection of the placenta" 130 : 4947-4953, 2020
• 11 Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor" 181 : 271-280, 2020
• 12 Hecht JL, "SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology : a series of 19 placentas from COVID-19-positive mothers" 33 : 2092-2103, 2020
• 13 Wardhana MP, "SARS-CoV-2 antibody test for the hospitalised emergency obstetric cases : useful or wasteful" 15 : 56-63, 2021
• 14 Remmele W, "Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue" 8 : 138-140, 1987
• 15 Faure-Bardon V, "Protein expression of angiotensin-converting enzyme 2, a SARS-CoV-2-specific receptor, in fetal and placental tissues throughout gestation : new insight for perinatal counseling" 57 : 242-247, 2021
• 16 Di Girolamo R, "Placental histopathology after SARS-CoV-2 infection in pregnancy : a systematic review and meta-analysis" 3 : 100468-, 2021
• 17 Celik E, "Placental deficiency during maternal SARS-CoV-2 infection" 117 : 47-56, 2022
• 18 Di Mascio D, "Outcome of coronavirus spectrum infections(SARS, MERS, COVID-19)during pregnancy : a systematic review and meta-analysis" 2 : 100107-, 2020
• 19 Wardhana MP, "L-arginine protective effect on systemic blood pressure and placental expression of endoglin, transforming growth factor-β1 in the preeclampsia mice model" 9 : 29-34, 2021
• 20 Argueta LB, "Inflammatory responses in the placenta upon SARS-CoV-2 infection late in pregnancy" 25 : 104223-, 2022
• 21 Brum AC, "Impact of perinatal COVID on fetal and neonatal brain and neurodevelopmental outcomes" 28 : 101427-, 2023
• 22 Sun QH, "IFN-γ promotes apoptosis of the uterus and placenta in pregnant rat and human cytotrophoblast cells" 27 : 567-578, 2007
• 23 Fatih TAS¸, "Histopathological examination of the placenta after delivery in pregnant women with COVID-19" 5 : 868-874, 2022
• 24 Cascella M, "Features, evaluation, and treatment of coronavirus (COVID-19)" StatPearls Publishing; 2023
• 25 Bloise E, "Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia" 224 : 298-, 2021
• 26 Das¸ T, "Evaluation of postmortem pathological changes in the lung in SARS-CoV-2 RT-PCR positive cases" 5 : 1113-1120, 2021
• 27 Sheibak N, "Elevated immunoexpression of interferon-gamma in placenta tissue samples from pregnancies complicated with preeclampsia compared to the placenta previa" 22 : 175-180, 2020
• 28 Bwire GM, "Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens : a systematic review and meta-analysis" 93 : 719-725, 2021
• 29 Heerema-McKenney A, "Defense and infection of the human placenta" 126 : 570-588, 2018
• 30 Juttukonda LJ, "Decidual immune response following COVID-19 during pregnancy varies by timing of maternal SARS-CoV-2 infection" 151 : 103501-, 2022
• 31 Mullins E, "Coronavirus in pregnancy and delivery : rapid review" 55 : 586-592, 2020
• 32 Taglauer E, "Consistent localization of SARS-CoV-2 spike glycoprotein and ACE2 over TMPRSS2 predominance in placental villi of 15COVID-19 positive maternal-fetal dyads" 100 : 69-74, 2020
• 33 Ellington S, "Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–June 7, 2020" 69 : 769-775, 2020
• 34 Shook LL, "COVID-19 in pregnancy : implications for fetal brain development" 28 : 319-330, 2022
• 35 World Health Organization, "COVID-19 clinical management: living guidance, 25 January 2021"
• 36 Soullane S, "Association of placental pathology and gross morphology with autism spectrum disorders" 15 : 531-538, 2022
• 37 Rebutini PZ, "Association between COVID-19 pregnant women symptoms severity and placental morphologic features" 12 : 685919-, 2021
• 38 Kokawa K, "Apoptosis and the expression of Bax and Bcl-2 in hyperplasia and adenocarcinoma of the uterine endometrium" 16 : 2211-2218, 2001
• 39 McDonald AJ, "Anticipating the long-term neurodevelopmental impact of the COVID-19 pandemic on newborns and infants : a call for research and preventive policy" 6 : 100213-, 2021
• 40 Fenizia C, "Analysis of SARS-CoV-2 vertical transmission during pregnancy" 11 : 5128-, 2020